Left atrial appendage occlusion

Oluseun Alli, David Holmes

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic complications from AF continues to be central in the management of these patients. The role of LAA as a nidus for thrombus formation is well documented. Multiple approaches to exclude the LAA from the circulation either percutaneously or surgically have been described and are undergoing testing. Although pharmacological therapy for stroke prevention remains the cornerstone of treatment, device and surgical exclusion of the LAA have proven to be viable alternatives in carefully selected patients. Even though current evidence show that LAA occlusion is safe and effective, approval and adoption of this strategy has been quite difficult due to paucity of randomised clinical trial data on the risk and benefit ratio, cost effectiveness and the issues of procedural risk as well as longer-term outcome. This review aims to provide an update on the current status of LAA occlusion, specifically looking at interpretation of current clinical data, available techniques and devices, issues with current devices and future direction.

Original languageEnglish (US)
Pages (from-to)834-841
Number of pages8
JournalHeart
Volume101
Issue number11
DOIs
StatePublished - Jun 1 2015

Fingerprint

Atrial Appendage
Equipment and Supplies
Atrial Fibrillation
Cost-Benefit Analysis
Stroke
Thromboembolism
Thrombosis
Cardiovascular Diseases
Randomized Controlled Trials
Odds Ratio
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Left atrial appendage occlusion. / Alli, Oluseun; Holmes, David.

In: Heart, Vol. 101, No. 11, 01.06.2015, p. 834-841.

Research output: Contribution to journalReview article

Alli, Oluseun ; Holmes, David. / Left atrial appendage occlusion. In: Heart. 2015 ; Vol. 101, No. 11. pp. 834-841.
@article{46a2c14e2db443a7a74e2988419fa56f,
title = "Left atrial appendage occlusion",
abstract = "Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic complications from AF continues to be central in the management of these patients. The role of LAA as a nidus for thrombus formation is well documented. Multiple approaches to exclude the LAA from the circulation either percutaneously or surgically have been described and are undergoing testing. Although pharmacological therapy for stroke prevention remains the cornerstone of treatment, device and surgical exclusion of the LAA have proven to be viable alternatives in carefully selected patients. Even though current evidence show that LAA occlusion is safe and effective, approval and adoption of this strategy has been quite difficult due to paucity of randomised clinical trial data on the risk and benefit ratio, cost effectiveness and the issues of procedural risk as well as longer-term outcome. This review aims to provide an update on the current status of LAA occlusion, specifically looking at interpretation of current clinical data, available techniques and devices, issues with current devices and future direction.",
author = "Oluseun Alli and David Holmes",
year = "2015",
month = "6",
day = "1",
doi = "10.1136/heartjnl-2014-306255",
language = "English (US)",
volume = "101",
pages = "834--841",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Left atrial appendage occlusion

AU - Alli, Oluseun

AU - Holmes, David

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic complications from AF continues to be central in the management of these patients. The role of LAA as a nidus for thrombus formation is well documented. Multiple approaches to exclude the LAA from the circulation either percutaneously or surgically have been described and are undergoing testing. Although pharmacological therapy for stroke prevention remains the cornerstone of treatment, device and surgical exclusion of the LAA have proven to be viable alternatives in carefully selected patients. Even though current evidence show that LAA occlusion is safe and effective, approval and adoption of this strategy has been quite difficult due to paucity of randomised clinical trial data on the risk and benefit ratio, cost effectiveness and the issues of procedural risk as well as longer-term outcome. This review aims to provide an update on the current status of LAA occlusion, specifically looking at interpretation of current clinical data, available techniques and devices, issues with current devices and future direction.

AB - Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic complications from AF continues to be central in the management of these patients. The role of LAA as a nidus for thrombus formation is well documented. Multiple approaches to exclude the LAA from the circulation either percutaneously or surgically have been described and are undergoing testing. Although pharmacological therapy for stroke prevention remains the cornerstone of treatment, device and surgical exclusion of the LAA have proven to be viable alternatives in carefully selected patients. Even though current evidence show that LAA occlusion is safe and effective, approval and adoption of this strategy has been quite difficult due to paucity of randomised clinical trial data on the risk and benefit ratio, cost effectiveness and the issues of procedural risk as well as longer-term outcome. This review aims to provide an update on the current status of LAA occlusion, specifically looking at interpretation of current clinical data, available techniques and devices, issues with current devices and future direction.

UR - http://www.scopus.com/inward/record.url?scp=84930627718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930627718&partnerID=8YFLogxK

U2 - 10.1136/heartjnl-2014-306255

DO - 10.1136/heartjnl-2014-306255

M3 - Review article

C2 - 25518846

AN - SCOPUS:84930627718

VL - 101

SP - 834

EP - 841

JO - Heart

JF - Heart

SN - 1355-6037

IS - 11

ER -